| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5883232 | Clinical Lymphoma Myeloma and Leukemia | 2013 | 6 Pages |
Abstract
The use of a RAP to identify patients likely to benefit from prophylactic filgrastim is safe and results in cost savings. Patients with myeloma benefit from earlier introduction of filgrastim in terms of neutrophil recovery; this disease-specific observation is an important consideration for future studies.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Amit Khot, Michael Dickinson, Kerrie Stokes, Simon Harrison, Kate Burbury, Shaun Fleming, Dominic Wall, Peter Gambell, H. Miles Prince, John F. Seymour, David Ritchie,